As a GLP-1 receptor agonist, semaglutide slows the rate at which food moves from the stomach into the small intestine
Last reviewed: May 16, 2026 Last updated: May 16, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Individual responses vary, and compounded tirzepatide has not been reviewed or approved by the FDA for safety or effectiveness
They enhance insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycaemia and concurrently suppressing glucagon secretion, leading to decreased hepatic glucose production [2]
Int J Mol Med (2019) 44(1):21826